119 related articles for article (PubMed ID: 34219432)
1. Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma.
Jiang X; Song TT; Hao F
Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):548-551. PubMed ID: 34219432
[No Abstract] [Full Text] [Related]
2. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
Lederhandler M; Beasley JM; Brinster NK; Nagler AR
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677801
[TBL] [Abstract][Full Text] [Related]
3. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Cho SL; Lin WC; Chuang CA; Liao WY; Lai CF
Nephrology (Carlton); 2020 Sep; 25(9):730. PubMed ID: 32364270
[No Abstract] [Full Text] [Related]
4. Reactive perforating collagenosis during erlotinib therapy.
Suzuki Y; Yamamoto T
Acta Derm Venereol; 2012 Mar; 92(2):216-7. PubMed ID: 22101862
[No Abstract] [Full Text] [Related]
5. Acquired reactive perforating collagenosis: current status.
Karpouzis A; Giatromanolaki A; Sivridis E; Kouskoukis C
J Dermatol; 2010 Jul; 37(7):585-92. PubMed ID: 20629824
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
Dasanu CA; Alvarez-Argote J; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2018 Apr; 24(3):229-231. PubMed ID: 28436313
[TBL] [Abstract][Full Text] [Related]
7. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient.
Hecimovic A; Vukic Dugac A; Jankovic Makek M; Cikes M; Samarzija M; Jakopovic M
Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31315351
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Tanaka H; Inomata M; Hayashi R; Shimokawa K; Tokui K; Okazawa S; Kambara K; Yamada T; Miwa T; Kashii T; Konishi H; Tobe K
Gan To Kagaku Ryoho; 2017 Jul; 44(7):595-597. PubMed ID: 28790264
[TBL] [Abstract][Full Text] [Related]
9. Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma.
Ma SH; Li CY
Lung Cancer; 2020 Oct; 148():173-174. PubMed ID: 32773208
[No Abstract] [Full Text] [Related]
10. Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Kau HC; Tsai CC
Cutan Ocul Toxicol; 2016 Sep; 35(3):257-9. PubMed ID: 26340340
[TBL] [Abstract][Full Text] [Related]
11. [A case of Sweet syndrome in a patient receiving erlotinib for lung adenocarcinoma].
Ahangari D; Ngendahayo P; Colinet B; Roquet-Gravy PP
Ann Dermatol Venereol; 2020 Mar; 147(3):202-206. PubMed ID: 32029299
[TBL] [Abstract][Full Text] [Related]
12. Eyelash trichomegaly induced by erlotinib for metastatic lung cancer.
Chan JYY; Kwok TYT; Yuen HKL
Hong Kong Med J; 2021 Feb; 27(1):60.e1-60.e3. PubMed ID: 33568562
[No Abstract] [Full Text] [Related]
13. Acquired Perforating Collagenosis in Diabetes Mellitus.
Gratsias E; Dissemond J
Dtsch Arztebl Int; 2018 Jul; 115(27-28):462. PubMed ID: 30064625
[No Abstract] [Full Text] [Related]
14. [Acquired reactive perforating collagenosis as a paraneoplastic syndrome of lung adenocarcinoma].
Lova-Navarro M; Godoy-Díaz DJ; Fernández-Ballesteros MD; Vera-Casaño Á
Med Clin (Barc); 2014 May; 142(9):e17. PubMed ID: 24210984
[No Abstract] [Full Text] [Related]
15. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer.
Tsutsui K; Namikawa K; Mori T; Kato K; Jinnai S; Nakama K; Ogata D; Takahashi A; Yamazaki N
J Dermatol; 2021 Feb; 48(2):e114-e115. PubMed ID: 33264448
[No Abstract] [Full Text] [Related]
16. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease.
Calista D; Morri M
Eur J Dermatol; 2008; 18(1):84-5. PubMed ID: 18086600
[No Abstract] [Full Text] [Related]
17. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
18. Acquired reactive perforating collagenosis associated with Hodgkin disease.
Rivera-Rodríguez A; Prieto-Torres L; Felipo-Berlanga F; Ara-Martín M
Clin Exp Dermatol; 2017 Dec; 42(8):934-936. PubMed ID: 28691303
[No Abstract] [Full Text] [Related]
19. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
Erikson AK; Yu NY; Sheedy JT; Shoudis SN; Paripati HR; Sio TT
Pract Radiat Oncol; 2019 May; 9(3):128-131. PubMed ID: 30770236
[No Abstract] [Full Text] [Related]
[Next] [New Search]
